# A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

> **NCT01889069** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 159 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT01889069
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-31
- **Primary completion:** 2019-05-28
- **Final completion:** 2019-05-28
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889069, "A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01889069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*